Last update 08 May 2025

p53 x ASXL1 x PS x RUNX1

Basic Info

Related Targets
p53ASXL1PS[+1]

Related

1
Drugs associated with p53 x ASXL1 x PS x RUNX1
CER-1236
Target
ASXL1 x PS x RUNX1 x p53
Mechanism
ASXL1 modulators [+3]
Active Org.
CERo Therapeutics Holdings, Inc. [+1]
Originator Org.
CERo Therapeutics, Inc.CERo Therapeutics, Inc.
Active Indication
Refractory acute myeloid leukemia [+4]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
1
Clinical Trials associated with p53 x ASXL1 x PS x RUNX1
NCT06834282
/ RecruitingPhase 1
Phase 1/1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia (CertainT-1)
100 Clinical Results associated with p53 x ASXL1 x PS x RUNX1
Login to view more data
100 Translational Medicine associated with p53 x ASXL1 x PS x RUNX1
Login to view more data
0 Patents (Medical) associated with p53 x ASXL1 x PS x RUNX1
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free